Adaptimmune Therapeutics PLC

Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.

ADAP | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 60 JUBILEE AVENUE, 0 ABINGDON, OXFORDSHIRE
Website:: https://www.adaptimmune.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company focused on developing novel cell therapies for cancer patients. The company specializes in treating challenging solid tumors through its proprietary T-cell therapy platform, which engineers a patient's own cells to identify and combat cancer. This personalized approach aims to harness the patient's immune system to provide transformative treatments. Adaptimmune maintains a robust pipeline of immunotherapy products to advance cancer care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Adaptimmune Therapeutics PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Adaptimmune Therapeutics PLC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Adaptimmune Therapeutics PLC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
AroCell AB Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.	Sweden	AROC
ArriVent BioPharma, Inc. A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.	United States of America	AVBP
ARROWHEAD PHARMACEUTICALS, INC. Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.	United States of America	ARWR
ARS Pharmaceuticals, Inc. Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.	United States of America	SPRY
ARTELO BIOSCIENCES, INC. Develops lipid-signaling therapeutics for cancer, pain, anxiety, and depression.	United States of America	ARTL
Artiva Biotherapeutics, Inc. Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.	United States of America	ARTV
Ascelia Pharma Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.	Sweden	ACE
Ascendis Pharma A/S Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.	United States of America	ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Biopharma developing small-molecule drugs for cancer, HBV, and age-related diseases.	United States of America	AAPG
ASKA Pharmaceutical Holdings CO., Ltd. Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.	Japan	4886